Aveanna Healthcare (AVAH) Financials

$5.49 -0.26 (-4.52%)

Closing price 05/21/2025 04:00 PM Eastern

Extended Trading

$5.48 0.00 (-0.09%)

As of 05/21/2025 04:04 PM Eastern

Annual Income Statements for Aveanna Healthcare

This table shows Aveanna Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/28/2024	12/30/2023	12/31/2022	1/2/2021	12/28/2019
Net Income / (Loss) Attributable to Common Shareholders	-11	-135	-662	-57	-77
Consolidated Net Income / (Loss)	-11	-135	-662	-57	-77
Net Income / (Loss) Continuing Operations	-11	-135	-662	-57	-77
Total Pre-Tax Income	5.07	-139	-664	-52	-75
Total Operating Income	140	8.07	-642	-3.49	39
Total Gross Profit	636	595	553	455	419
Total Revenue	2,025	1,895	1,788	1,495	1,384
Operating Revenue	2,025	1,895	1,788	1,495	1,384
Total Cost of Revenue	1,389	1,300	1,234	1,041	965
Operating Cost of Revenue	1,389	1,300	1,234	1,041	965
Total Operating Expenses	496	587	1,196	458	380
Selling, General & Admin Expense	353	361	357	241	228
Depreciation Expense	11	14	21	17	14
Other Operating Expenses / (Income)	131	107	142	115	116
Impairment Charge	0.00	105	675	76	0.00
Restructuring Charge	1.49	0.47	0.10	9.56	23
Total Other Income / (Expense), net	-135	-147	-22	-48	-114
Interest Expense	157	153	108	83	97
Interest & Investment Income	0.50	0.33	0.68	0.35	0.21
Other Income / (Expense), net	21	5.85	86	34	-17
Income Tax Expense	16	-4.47	-1.78	5.32	1.49
Basic Earnings per Share	($0.06)	($0.71)	($3.57)	($0.40)	($0.56)
Weighted Average Basic Shares Outstanding	192.89M	189.96M	185.55M	140.97M	136.91M
Diluted Earnings per Share	($0.06)	($0.71)	($3.57)	($0.40)	($0.56)
Weighted Average Diluted Shares Outstanding	192.89M	189.96M	185.55M	140.97M	136.91M
Weighted Average Basic & Diluted Shares Outstanding	195.09M	192.38M	185.86M	140.97M	136.91M

This table shows Aveanna Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/29/2025	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	10/1/2022
Net Income / (Loss) Attributable to Common Shareholders	5.19	29	-43	14	-11	-26	-102	26	-32	-238	24
Consolidated Net Income / (Loss)	5.19	29	-43	14	-11	-26	-102	26	-32	-238	24
Net Income / (Loss) Continuing Operations	5.19	29	-43	14	-11	-26	-102	26	-32	-238	24
Total Pre-Tax Income	10	27	-27	3.98	1.49	-32	-102	25	-30	-239	22
Total Operating Income	52	46	34	37	23	29	-76	37	18	-204	4.79
Total Gross Profit	184	172	160	158	146	148	147	155	144	129	135
Total Revenue	559	520	509	505	491	479	478	472	466	451	443
Operating Revenue	559	520	509	505	491	479	478	472	466	451	443
Total Cost of Revenue	376	348	349	347	345	330	331	317	322	322	308
Operating Cost of Revenue	376	348	349	347	345	330	331	317	322	322	308
Total Operating Expenses	132	126	126	121	123	119	224	118	127	333	130
Selling, General & Admin Expense	91	89	88	88	88	87	91	91	92	90	90
Depreciation Expense	2.59	2.45	2.59	2.83	2.91	3.28	2.96	3.49	4.04	4.54	4.92
Other Operating Expenses / (Income)	38	33	35	30	32	29	24	23	31	34	35
Impairment Charge	0.00	-	0.00	0.00	0.00	-	105	0.00	0.00	-	0.00
Restructuring Charge	0.11	1.34	0.15	0.00	0.00	-	0.43	-0.03	0.07	0.03	0.00
Total Other Income / (Expense), net	-42	-19	-61	-33	-21	-61	-25	-13	-48	-35	17
Interest Expense	36	38	39	40	40	40	40	38	36	34	28
Interest & Investment Income	0.13	0.20	0.10	0.10	0.10	0.09	0.05	0.11	0.08	0.31	0.16
Other Income / (Expense), net	-5.45	19	-22	6.37	18	-21	14	25	-12	-1.02	45
Income Tax Expense	4.96	-2.25	16	-9.93	13	-5.86	0.63	-0.81	1.57	-1.36	-2.67
Basic Earnings per Share	$0.03	$0.15	($0.22)	$0.07	($0.06)	($0.14)	($0.54)	$0.14	($0.17)	($1.28)	$0.13
Weighted Average Basic Shares Outstanding	194.67M	192.89M	193.36M	192.60M	192.24M	189.96M	189.14M	189.07M	189.05M	185.55M	186.11M
Diluted Earnings per Share	$0.03	$0.15	($0.22)	$0.07	($0.06)	($0.13)	($0.54)	$0.13	($0.17)	($1.28)	$0.13
Weighted Average Diluted Shares Outstanding	206.24M	192.89M	193.36M	196.87M	192.24M	189.96M	189.14M	189.74M	189.05M	185.55M	186.17M
Weighted Average Basic & Diluted Shares Outstanding	195.09M	195.09M	193.23M	193.23M	192.38M	192.38M	190.73M	190.43M	185.86M	185.86M	185.92M

This table details how cash moves in and out of Aveanna Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/28/2024	12/30/2023	12/31/2022	1/2/2021	12/28/2019
Net Change in Cash & Equivalents	40	25	-8.22	134	-4.67
Net Cash From Operating Activities	33	23	-48	117	-8.71
Net Cash From Continuing Operating Activities	33	23	-48	117	-8.71
Net Income / (Loss) Continuing Operations	-11	-135	-662	-57	-77
Consolidated Net Income / (Loss)	-11	-135	-662	-57	-77
Depreciation Expense	11	14	21	17	14
Amortization Expense	5.46	5.18	25	7.53	6.72
Non-Cash Adjustments To Reconcile Net Income	56	161	609	99	35
Changes in Operating Assets and Liabilities, net	-29	-22	-42	50	12
Net Cash From Investing Activities	-6.32	-8.79	-25	-194	-18
Net Cash From Continuing Investing Activities	-6.32	-8.79	-25	-194	-18
Purchase of Property, Plant & Equipment	-6.32	-6.12	-12	-15	-17
Other Investing Activities, net	0.00	-2.68	0.00	0.00	-0.23
Net Cash From Financing Activities	14	11	62	211	22
Net Cash From Continuing Financing Activities	14	11	65	211	22
Repayment of Debt	-29	-75	-54	120	17
Issuance of Debt	25	70	115	14	610
Issuance of Common Equity	3.09	0.95	4.02	50	0.00
Other Financing Activities, net	15	15	0.73	29	-606
Cash Interest Paid	153	138	103	73	93
Cash Income Taxes Paid	5.71	1.14	1.59	2.17	1.55

This table details how cash moves in and out of Aveanna Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/29/2025	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	10/1/2022
Net Change in Cash & Equivalents	-13	5.83	31	5.05	-1.34	-4.35	20	-6.42	15	-41	46
Net Cash From Operating Activities	-8.63	13	29	1.81	-12	-3.01	29	-11	7.50	-40	21
Net Cash From Continuing Operating Activities	-8.63	13	29	1.81	-12	-3.01	29	-11	7.50	-40	21
Net Income / (Loss) Continuing Operations	5.19	29	-43	14	-11	-26	-102	26	-32	-238	24
Consolidated Net Income / (Loss)	5.19	29	-43	14	-11	-26	-102	26	-32	-238	24
Depreciation Expense	2.59	2.45	2.59	2.83	2.91	3.28	2.96	3.49	4.04	4.54	4.92
Amortization Expense	1.65	1.66	1.31	-4.97	7.46	-11	14	-2.94	5.66	7.34	14
Non-Cash Adjustments To Reconcile Net Income	27	-1.93	45	18	-3.97	51	94	-5.73	21	213	-48
Changes in Operating Assets and Liabilities, net	-45	-18	24	-28	-7.20	-20	20	-31	8.75	-27	25
Net Cash From Investing Activities	-2.35	-1.53	-2.21	-1.27	-1.31	-1.57	-1.13	-1.30	-4.80	-3.20	-3.64
Net Cash From Continuing Investing Activities	-2.35	-1.53	-2.21	-1.27	-1.31	-1.57	-1.13	-1.30	-4.80	-3.20	-3.64
Purchase of Property, Plant & Equipment	-2.35	-1.53	-2.21	-1.27	-1.31	-1.57	-1.13	-1.30	-2.12	-3.21	-2.82
Net Cash From Financing Activities	-1.81	-6.05	3.62	4.51	12	0.22	-7.29	5.40	13	-1.03	29
Net Cash From Continuing Financing Activities	-1.81	-6.05	3.62	4.51	12	0.22	-7.29	5.40	13	2.02	29
Repayment of Debt	-5.06	-9.79	-1.06	-4.75	-14	-9.83	-11	-9.23	-45	-4.59	-31
Issuance of Debt	0.00	-	-	5.00	20	5.00	-	10	55	-	60
Issuance of Common Equity	1.79	0.00	1.74	-	1.35	-	-	0.95	0.00	1.74	-
Other Financing Activities, net	1.46	3.74	2.95	4.26	4.28	5.05	3.22	3.68	3.01	4.87	-0.03
Cash Interest Paid	35	38	38	39	38	39	39	36	24	33	27
Cash Income Taxes Paid	-0.46	0.07	0.71	5.00	-0.06	0.37	0.61	0.54	-0.39	0.18	0.41

This table presents Aveanna Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020
Period end date	12/28/2024	12/30/2023	12/31/2022	1/2/2021	1/2/2021
Total Assets	1,663	1,613	1,712	1,844	1,844
Total Current Assets	393	315	270	341	341
Cash & Equivalents	84	44	19	137	137
Accounts Receivable	265	237	221	173	173
Prepaid Expenses	17	16	15	11	11
Other Current Assets	26	19	14	19	19
Plant, Property, & Equipment, net	17	21	23	33	33
Total Noncurrent Assets	1,253	1,278	1,419	1,471	1,471
Noncurrent Note & Lease Receivables	22	21	23	24	24
Goodwill	1,055	1,055	1,160	1,316	1,316
Intangible Assets	90	94	96	74	74
Other Noncurrent Operating Assets	87	108	141	54	54
Total Liabilities & Shareholders' Equity	1,663	1,613	1,712	1,844	1,844
Total Liabilities	1,785	1,740	1,716	1,577	1,577
Total Current Liabilities	402	355	326	260	260
Short-Term Debt	9.20	9.20	9.20	9.91	13
Accounts Payable	36	30	45	57	57
Accrued Expenses	88	67	44	57	57
Other Taxes Payable	0.00	0.00	0.00	25	25
Other Current Liabilities	269	248	229	112	107
Total Noncurrent Liabilities	1,385	1,388	1,392	1,319	1,319
Long-Term Debt	1,272	1,276	1,281	1,163	1,163
Asset Retirement Reserve & Litigation Obligation	67	62	58	54	54
Noncurrent Deferred & Payable Income Tax Liabilities	5.89	4.86	3.84	27	27
Other Noncurrent Operating Liabilities	40	45	48	73	73
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-124	-130	-6.31	265	265
Total Preferred & Common Equity	-124	-130	-6.31	265	265
Preferred Stock	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-124	-130	-6.31	265	265
Common Stock	1,259	1,242	1,230	723	723
Retained Earnings	-1,382	-1,371	-1,237	-458	-458

This table presents Aveanna Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/29/2025	9/28/2024	6/29/2024	3/30/2024	9/30/2023	7/1/2023	4/1/2023	10/1/2022
Total Assets	1,661	1,644	1,664	1,643	1,655	1,741	1,731	1,973
Total Current Assets	408	381	364	336	318	301	308	312
Cash & Equivalents	71	78	48	43	48	28	34	64
Accounts Receivable	295	265	273	258	236	237	242	219
Prepaid Expenses	20	12	17	16	12	16	17	13
Other Current Assets	21	25	27	20	22	20	16	17
Plant, Property, & Equipment, net	19	18	19	19	22	20	21	25
Total Noncurrent Assets	1,234	1,245	1,281	1,287	1,314	1,420	1,401	1,636
Noncurrent Note & Lease Receivables	18	26	24	25	23	27	24	24
Goodwill	1,055	1,055	1,055	1,055	1,055	1,160	1,160	1,368
Intangible Assets	89	90	93	93	95	97	98	98
Other Noncurrent Operating Assets	72	75	110	115	142	136	119	146
Total Liabilities & Shareholders' Equity	1,661	1,644	1,664	1,643	1,655	1,741	1,731	1,973
Total Liabilities	1,759	1,799	1,782	1,777	1,758	1,746	1,765	1,743
Total Current Liabilities	388	406	389	382	364	356	376	352
Short-Term Debt	9.20	9.20	9.20	9.20	9.20	9.20	9.20	9.20
Accounts Payable	30	42	39	43	37	38	43	49
Current Employee Benefit Liabilities	86	85	73	69	76	-	62	50
Other Current Liabilities	263	270	268	261	243	248	262	218
Total Noncurrent Liabilities	1,373	1,395	1,394	1,397	1,396	1,393	1,391	1,394
Long-Term Debt	1,271	1,275	1,274	1,275	1,278	1,279	1,280	1,283
Capital Lease Obligations	29	33	-	39	43	-	43	45
Asset Retirement Reserve & Litigation Obligation	64	73	24	72	67	64	61	61
Noncurrent Deferred & Payable Income Tax Liabilities	6.51	5.39	5.47	5.47	4.42	4.44	4.44	2.75
Other Noncurrent Operating Liabilities	2.26	7.31	91	5.94	4.04	45	2.45	2.75
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-100	-156	-119	-136	-106	-6.74	-36	228
Total Preferred & Common Equity	-100	-156	-119	-136	-106	-6.74	-36	228
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-100	-156	-119	-136	-106	-6.74	-36	228
Common Stock	1,277	1,255	1,250	1,246	1,240	1,236	1,233	1,227
Retained Earnings	-1,377	-1,411	-1,369	-1,382	-1,345	-1,243	-1,269	-999

This table displays calculated financial ratios and metrics derived from Aveanna Healthcare's official financial filings.

Metric	2024	2023	2022	2021	2020
Period end date	12/28/2024	12/30/2023	12/31/2022	1/2/2021	12/28/2019
Growth Metrics	-	-	-	-	-
Revenue Growth	6.82%	6.02%	19.57%	8.02%	0.00%
EBITDA Growth	439.58%	106.44%	-1,018.61%	29.28%	0.00%
EBIT Growth	1,057.62%	102.50%	-1,897.38%	41.34%	0.00%
NOPAT Growth	-5,430.76%	101.26%	-18,319.16%	-108.95%	0.00%
Net Income Growth	91.88%	79.68%	-1,060.45%	25.44%	0.00%
EPS Growth	91.55%	80.11%	-792.50%	28.57%	0.00%
Operating Cash Flow Growth	43.95%	146.84%	-141.50%	1,438.28%	0.00%
Free Cash Flow Firm Growth	-265.55%	138.32%	-14,707.44%	0.00%	0.00%
Invested Capital Growth	-3.51%	-12.08%	-2.79%	-0.40%	0.00%
Revenue Q/Q Growth	2.07%	1.48%	14.08%	-5.12%	0.00%
EBITDA Q/Q Growth	42.15%	120.46%	-42.00%	-43.95%	0.00%
EBIT Q/Q Growth	54.43%	106.98%	-40.54%	-62.84%	0.00%
NOPAT Q/Q Growth	-448.96%	103.58%	-23.93%	-102.54%	0.00%
Net Income Q/Q Growth	83.40%	61.18%	-34.98%	-184.54%	0.00%
EPS Q/Q Growth	82.35%	61.83%	-29.82%	-135.29%	0.00%
Operating Cash Flow Q/Q Growth	101.14%	255.73%	-156.11%	211.44%	0.00%
Free Cash Flow Firm Q/Q Growth	-246.63%	-5.30%	-6.54%	0.00%	0.00%
Invested Capital Q/Q Growth	-0.91%	-5.39%	-15.72%	-11.82%	0.00%
Profitability Metrics	-	-	-	-	-
Gross Margin	31.39%	31.42%	30.95%	30.40%	30.29%
EBITDA Margin	8.76%	1.73%	-28.54%	3.71%	3.10%
Operating Margin	6.90%	0.43%	-35.93%	-0.23%	2.81%
EBIT Margin	7.96%	0.73%	-31.15%	2.07%	1.58%
Profit (Net Income) Margin	-0.54%	-7.10%	-37.03%	-3.82%	-5.53%
Tax Burden Percent	-215.48%	96.78%	99.73%	110.28%	101.98%
Interest Burden Percent	3.15%	-998.32%	119.23%	-167.01%	-342.34%
Effective Tax Rate	315.48%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-27.57%	0.48%	-35.04%	-0.19%	2.09%
ROIC Less NNEP Spread (ROIC-NNEP)	-3.76%	-10.68%	-53.46%	-5.44%	-7.88%
Return on Net Nonoperating Assets (RNNOA)	36.21%	197.53%	-476.72%	-21.34%	-30.96%
Return on Equity (ROE)	8.64%	198.00%	-511.77%	-21.53%	-28.87%
Cash Return on Invested Capital (CROIC)	-24.00%	13.33%	-32.21%	0.22%	0.00%
Operating Return on Assets (OROA)	9.84%	0.84%	-31.32%	1.68%	1.19%
Return on Assets (ROA)	-0.67%	-8.09%	-37.24%	-3.09%	-4.15%
Return on Common Equity (ROCE)	8.64%	198.00%	-511.77%	-21.53%	-28.87%
Return on Equity Simple (ROE_SIMPLE)	8.85%	103.82%	0.00%	-21.53%	-28.87%
Net Operating Profit after Tax (NOPAT)	-301	5.65	-450	-2.44	27
NOPAT Margin	-14.88%	0.30%	-25.15%	-0.16%	1.97%
Net Nonoperating Expense Percent (NNEP)	-23.81%	11.16%	18.42%	5.26%	9.97%
Return On Investment Capital (ROIC_SIMPLE)	-26.03%	0.49%	-	-	-
Cost of Revenue to Revenue	68.61%	68.58%	69.05%	69.60%	69.71%
SG&A Expenses to Revenue	17.43%	19.05%	19.98%	16.12%	16.46%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	24.49%	30.99%	66.88%	30.63%	27.48%
Earnings before Interest and Taxes (EBIT)	161	14	-557	31	22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	177	33	-510	56	43
Valuation Ratios	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	1.73	1.73
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.44	0.27	0.08	0.31	0.33
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.95	1.58	1.12	1.15	1.15
Enterprise Value to Revenue (EV/Rev)	1.04	0.92	0.79	1.00	1.08
Enterprise Value to EBITDA (EV/EBITDA)	11.82	53.31	0.00	26.92	34.87
Enterprise Value to EBIT (EV/EBIT)	13.01	125.89	0.00	48.26	68.34
Enterprise Value to NOPAT (EV/NOPAT)	0.00	310.20	0.00	0.00	54.93
Enterprise Value to Operating Cash Flow (EV/OCF)	64.25	77.31	0.00	12.82	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	11.07	0.00	528.40	0.00
Leverage & Solvency	-	-	-	-	-
Debt to Equity	-10.37	-9.92	-204.48	4.43	4.44
Long-Term Debt to Equity	-10.29	-9.85	-203.02	4.39	4.39
Financial Leverage	-9.63	-18.49	8.92	3.92	3.93
Leverage Ratio	-12.94	-24.47	13.74	6.96	6.96
Compound Leverage Factor	-0.41	244.27	16.39	-11.62	-23.82
Debt to Total Capital	110.68%	111.21%	100.49%	81.57%	81.61%
Short-Term Debt to Total Capital	0.80%	0.80%	0.72%	0.69%	0.89%
Long-Term Debt to Total Capital	109.88%	110.41%	99.77%	80.89%	80.72%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-10.68%	-11.21%	-0.49%	18.43%	18.39%
Debt to EBITDA	7.22	39.10	-2.53	21.13	27.38
Net Debt to EBITDA	6.74	37.76	-2.49	18.65	24.18
Long-Term Debt to EBITDA	7.17	38.82	-2.51	20.95	27.08
Debt to NOPAT	-4.25	227.51	-2.87	-480.72	43.14
Net Debt to NOPAT	-3.97	219.74	-2.83	-424.46	38.10
Long-Term Debt to NOPAT	-4.22	225.89	-2.85	-476.66	42.67
Altman Z-Score	0.67	0.16	-1.03	0.75	0.67
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-
Current Ratio	0.98	0.89	0.83	1.31	1.31
Quick Ratio	0.87	0.79	0.74	1.19	1.19
Cash Flow Metrics	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-262	158	-413	2.83	0.00
Operating Cash Flow to CapEx	516.49%	370.70%	-402.91%	765.36%	-52.38%
Free Cash Flow to Firm to Interest Expense	-1.67	1.03	-3.84	0.03	0.00
Operating Cash Flow to Interest Expense	0.21	0.15	-0.45	1.40	-0.09
Operating Cash Flow Less CapEx to Interest Expense	0.17	0.11	-0.56	1.22	-0.26
Efficiency Ratios	-	-	-	-	-
Asset Turnover	1.24	1.14	1.01	0.81	0.75
Accounts Receivable Turnover	8.07	8.28	9.07	8.65	8.01
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	106.77	87.54	64.53	45.79	42.39
Accounts Payable Turnover	41.73	34.77	24.37	18.36	17.03
Days Sales Outstanding (DSO)	45.23	44.08	40.24	42.21	45.59
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	8.75	10.50	14.98	19.88	21.44
Cash Conversion Cycle (CCC)	36.48	33.59	25.26	22.33	24.15
Capital & Investment Metrics	-	-	-	-	-
Invested Capital	1,073	1,112	1,265	1,301	1,306
Invested Capital Turnover	1.85	1.59	1.39	1.15	1.06
Increase / (Decrease) in Invested Capital	-39	-153	-36	-5.27	0.00
Enterprise Value (EV)	2,097	1,753	1,416	1,495	1,498
Market Capitalization	900	511	145	459	459
Book Value per Share	($0.64)	($0.68)	($0.03)	$1.88	$1.94
Tangible Book Value per Share	($6.56)	($6.70)	($6.79)	($7.98)	($8.22)
Total Capital	1,157	1,156	1,284	1,438	1,441
Total Debt	1,281	1,286	1,290	1,173	1,176
Total Long-Term Debt	1,272	1,276	1,281	1,163	1,163
Net Debt	1,197	1,242	1,271	1,036	1,039
Capital Expenditures (CapEx)	6.32	6.12	12	15	17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-85	-75	-67	-47	-44
Debt-free Net Working Capital (DFNWC)	-0.30	-31	-48	90	93
Net Working Capital (NWC)	-9.50	-40	-57	80	80
Net Nonoperating Expense (NNE)	-290	140	212	55	104
Net Nonoperating Obligations (NNO)	1,197	1,242	1,271	1,036	1,041
Total Depreciation and Amortization (D&A)	16	19	47	25	21
Debt-free, Cash-free Net Working Capital to Revenue	-4.18%	-3.94%	-3.73%	-3.16%	-3.20%
Debt-free Net Working Capital to Revenue	-0.01%	-1.62%	-2.66%	6.03%	6.72%
Net Working Capital to Revenue	-0.47%	-2.10%	-3.17%	5.37%	5.80%
Earnings Adjustments	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.06)	($0.71)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	192.89M	189.96M	0.00	0.00	0.00
Adjusted Diluted Earnings per Share	($0.06)	($0.71)	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	192.89M	189.96M	0.00	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	195.09M	192.38M	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	99	80	23	57	43
Normalized NOPAT Margin	4.88%	4.20%	1.30%	3.83%	3.12%
Pre Tax Income Margin	0.25%	-7.33%	-37.13%	-3.46%	-5.42%
Debt Service Ratios	-	-	-	-	-
EBIT to Interest Expense	1.03	0.09	-5.17	0.37	0.23
NOPAT to Interest Expense	-1.92	0.04	-4.17	-0.03	0.28
EBIT Less CapEx to Interest Expense	0.99	0.05	-5.28	0.19	0.05
NOPAT Less CapEx to Interest Expense	-1.96	0.00	-4.29	-0.21	0.11
Payout Ratios	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-3.69%	0.00%

This table displays calculated financial ratios and metrics derived from Aveanna Healthcare's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/29/2025	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	10/1/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.98%	8.57%	6.49%	7.00%	5.20%	6.14%	7.90%	6.54%	3.52%	95.68%	7.72%
EBITDA Growth	12.00%	689,300.00%	134.54%	-34.57%	239.32%	100.01%	-165.68%	114.25%	-73.79%	-353.31%	184.12%
EBIT Growth	12.95%	708.37%	118.99%	-30.58%	652.80%	103.90%	-224.60%	113.88%	-89.15%	-357.92%	179.92%
NOPAT Growth	115.46%	141.82%	144.56%	235.12%	-1,488.55%	114.33%	-1,093.85%	112.12%	-1.18%	-154.23%	-86.12%
Net Income Growth	146.48%	213.38%	58.16%	-45.68%	65.09%	89.18%	-521.39%	105.40%	-226.30%	-259.19%	1,062.58%
EPS Growth	150.00%	215.38%	59.26%	-46.15%	64.71%	89.84%	-515.38%	105.08%	-221.43%	-178.26%	1,200.00%
Operating Cash Flow Growth	27.90%	546.12%	2.42%	117.20%	-259.73%	92.53%	35.43%	47.10%	179.09%	-142.61%	-40.82%
Free Cash Flow Firm Growth	162.99%	-48.86%	-57.20%	23.25%	-108.01%	262.22%	1,476.76%	182.80%	227.20%	-109.28%	98.63%
Invested Capital Growth	-0.67%	-3.51%	-7.87%	-10.91%	-9.29%	-12.08%	-21.67%	-12.40%	-34.49%	-2.79%	1.70%
Revenue Q/Q Growth	7.57%	2.13%	0.81%	2.92%	2.47%	0.17%	1.29%	1.19%	3.38%	1.84%	0.01%
EBITDA Q/Q Growth	-26.62%	338.75%	-62.01%	-19.54%	78.36%	100.02%	-171.97%	317.28%	107.82%	-379.52%	115.61%
EBIT Q/Q Growth	-28.50%	448.81%	-72.84%	6.00%	411.66%	112.89%	-199.28%	1,049.53%	102.65%	-511.56%	111.06%
NOPAT Q/Q Growth	-46.54%	108.20%	-81.64%	175.68%	-936.13%	138.37%	-238.04%	213.57%	108.63%	-2,761.37%	101.68%
Net Income Q/Q Growth	-82.20%	168.11%	-408.09%	224.47%	56.59%	74.86%	-499.97%	180.00%	86.54%	-1,078.59%	105.13%
EPS Q/Q Growth	-80.00%	168.18%	-414.29%	216.67%	53.85%	75.93%	-515.38%	176.47%	86.72%	-1,084.62%	105.08%
Operating Cash Flow Q/Q Growth	-164.39%	-54.39%	1,524.88%	115.11%	-298.40%	-110.47%	372.87%	-240.33%	118.63%	-289.87%	206.59%
Free Cash Flow Firm Q/Q Growth	-61.48%	-23.83%	-56.34%	591.75%	-131.28%	-36.26%	25.71%	-68.05%	733.69%	-440.99%	92.44%
Invested Capital Q/Q Growth	5.96%	-0.91%	-3.01%	-2.45%	2.93%	-5.39%	-6.21%	-0.69%	-0.23%	-15.72%	4.89%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	32.82%	33.03%	31.37%	31.34%	29.73%	31.00%	30.81%	32.90%	30.97%	28.54%	30.38%
EBITDA Margin	9.05%	13.26%	3.09%	8.19%	10.48%	0.00%	-9.52%	13.39%	3.25%	-42.91%	15.63%
Operating Margin	9.26%	8.80%	6.68%	7.35%	4.66%	6.12%	-15.97%	7.94%	3.78%	-45.32%	1.08%
EBIT Margin	8.29%	12.47%	2.32%	8.61%	8.36%	1.67%	-13.01%	13.28%	1.17%	-45.55%	11.27%
Profit (Net Income) Margin	0.93%	5.61%	-8.42%	2.75%	-2.28%	-5.37%	-21.42%	5.42%	-6.86%	-52.71%	5.48%
Tax Burden Percent	51.17%	108.33%	156.75%	349.48%	-749.80%	81.46%	100.62%	103.27%	105.15%	99.43%	112.34%
Interest Burden Percent	21.89%	41.55%	-231.37%	9.15%	3.63%	-393.95%	163.57%	39.56%	-558.28%	116.38%	43.32%
Effective Tax Rate	48.83%	-8.33%	0.00%	-249.48%	849.80%	0.00%	0.00%	-3.27%	0.00%	0.00%	-12.34%
Return on Invested Capital (ROIC)	8.70%	17.67%	8.22%	42.34%	-55.74%	6.83%	-15.61%	11.20%	3.00%	-44.20%	1.28%
ROIC Less NNEP Spread (ROIC-NNEP)	7.00%	16.00%	2.93%	33.06%	-43.31%	3.15%	-19.44%	10.15%	-0.47%	-52.41%	3.18%
Return on Net Nonoperating Assets (RNNOA)	-74.60%	-154.13%	-28.17%	-656.23%	648.79%	-58.22%	-406.13%	130.70%	-1.92%	-467.36%	6.45%
Return on Equity (ROE)	-65.90%	-136.45%	-19.95%	-613.89%	593.05%	-51.39%	-421.73%	141.90%	1.08%	-511.56%	7.72%
Cash Return on Invested Capital (CROIC)	6.52%	-24.00%	15.84%	12.30%	10.52%	13.33%	12.50%	5.68%	13.64%	-32.21%	-26.07%
Operating Return on Assets (OROA)	10.50%	15.41%	2.79%	9.88%	9.52%	1.91%	-13.40%	13.33%	1.03%	-45.80%	8.99%
Return on Assets (ROA)	1.18%	6.94%	-10.12%	3.16%	-2.59%	-6.13%	-22.05%	5.45%	-6.03%	-52.99%	4.38%
Return on Common Equity (ROCE)	-65.90%	-136.45%	-19.95%	-613.89%	593.05%	-51.39%	-421.73%	141.90%	1.08%	-511.56%	7.72%
Return on Equity Simple (ROE_SIMPLE)	-5.43%	0.00%	42.09%	105.40%	83.43%	0.00%	327.84%	3,263.77%	2,005.70%	0.00%	-215.16%
Net Operating Profit after Tax (NOPAT)	27	50	24	130	-171	21	-53	39	12	-143	5.38
NOPAT Margin	4.74%	9.54%	4.68%	25.70%	-34.94%	4.28%	-11.18%	8.20%	2.65%	-31.72%	1.21%
Net Nonoperating Expense Percent (NNEP)	1.69%	1.67%	5.29%	9.28%	-12.43%	3.68%	3.83%	1.05%	3.47%	8.21%	-1.90%
Return On Investment Capital (ROIC_SIMPLE)	2.19%	4.28%	-	-	-	1.77%	-	-	-	-	-
Cost of Revenue to Revenue	67.18%	66.97%	68.63%	68.66%	70.27%	69.00%	69.19%	67.10%	69.03%	71.46%	69.62%
SG&A Expenses to Revenue	16.34%	17.07%	17.32%	17.42%	17.92%	18.17%	19.04%	19.34%	19.66%	19.94%	20.21%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	23.56%	24.23%	24.69%	23.99%	25.07%	24.88%	46.78%	24.95%	27.19%	73.86%	29.30%
Earnings before Interest and Taxes (EBIT)	46	65	12	43	41	8.02	-62	63	5.45	-205	50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	51	69	16	41	51	0.01	-45	63	15	-194	69
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.22
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.50	0.44	0.50	0.27	0.25	0.27	0.12	0.17	0.11	0.08	0.18
Price to Earnings (P/E)	192.73	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.52%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.01	1.95	2.07	1.58	1.54	1.58	1.28	1.26	1.18	1.12	1.03
Enterprise Value to Revenue (EV/Rev)	1.09	1.04	1.13	0.90	0.92	0.92	0.81	0.86	0.83	0.79	0.99
Enterprise Value to EBITDA (EV/EBITDA)	12.50	11.82	17.93	27.78	20.59	53.31	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	13.72	13.01	21.45	58.22	35.55	125.89	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	34.20	0.00	25.93	195.12	189.05	310.20	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	63.51	64.25	137.94	113.73	549.10	77.31	0.00	0.00	0.00	0.00	17.99
Enterprise Value to Free Cash Flow (EV/FCFF)	30.70	0.00	12.52	12.12	13.90	11.07	9.02	20.63	6.86	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-13.07	-10.37	-8.42	-10.79	-9.71	-9.92	-12.58	-191.18	-37.14	-204.48	5.86
Long-Term Debt to Equity	-12.98	-10.29	-8.36	-10.71	-9.64	-9.85	-12.49	-189.81	-36.89	-203.02	5.82
Financial Leverage	-10.65	-9.63	-9.61	-19.85	-14.98	-18.49	20.89	12.88	4.06	8.92	2.03
Leverage Ratio	-13.97	-12.94	-12.58	-27.09	-19.60	-24.47	29.68	18.87	6.52	13.74	4.00
Compound Leverage Factor	-3.06	-5.38	29.12	-2.48	-0.71	96.39	48.55	7.47	-36.39	16.00	1.73
Debt to Total Capital	108.29%	110.68%	113.47%	110.22%	111.48%	111.21%	108.64%	100.53%	102.77%	100.49%	85.43%
Short-Term Debt to Total Capital	0.76%	0.80%	0.79%	0.79%	0.77%	0.80%	0.75%	0.72%	0.71%	0.72%	0.59%
Long-Term Debt to Total Capital	107.52%	109.88%	112.68%	109.43%	110.70%	110.41%	107.89%	99.81%	102.06%	99.77%	84.84%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-8.29%	-10.68%	-13.47%	-10.22%	-11.48%	-11.21%	-8.64%	-0.53%	-2.77%	-0.49%	14.57%
Debt to EBITDA	7.16	7.22	10.56	20.18	15.49	39.10	-8.27	-28.01	-2.41	-2.53	-3.72
Net Debt to EBITDA	6.77	6.74	9.93	19.43	14.99	37.76	-7.97	-27.40	-2.35	-2.49	-3.54
Long-Term Debt to EBITDA	7.11	7.17	10.49	20.03	15.38	38.82	-8.21	-27.81	-2.39	-2.51	-3.69
Debt to NOPAT	19.59	-4.25	15.27	141.74	142.17	227.51	-8.42	-12.73	-2.98	-2.87	-3.68
Net Debt to NOPAT	18.52	-3.97	14.36	136.47	137.59	219.74	-8.11	-12.45	-2.90	-2.83	-3.51
Long-Term Debt to NOPAT	19.45	-4.22	15.16	140.72	141.18	225.89	-8.36	-12.64	-2.96	-2.85	-3.66
Altman Z-Score	0.56	0.48	0.34	0.27	0.20	0.15	-0.09	0.24	0.05	-0.35	0.24
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.05	0.98	0.94	0.94	0.88	0.89	0.87	0.85	0.82	0.83	0.89
Quick Ratio	0.94	0.87	0.85	0.82	0.79	0.79	0.78	0.75	0.74	0.74	0.80
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	34	89	116	266	-54	173	272	216	677	-107	-20
Operating Cash Flow to CapEx	-367.63%	876.78%	1,328.24%	142.55%	-915.29%	-191.65%	2,546.58%	-809.70%	353.20%	-1,252.29%	752.79%
Free Cash Flow to Firm to Interest Expense	0.94	2.33	2.96	6.73	-1.37	4.36	6.86	5.69	18.82	-3.14	-0.69
Operating Cash Flow to Interest Expense	-0.24	0.35	0.75	0.05	-0.30	-0.08	0.72	-0.28	0.21	-1.18	0.74
Operating Cash Flow Less CapEx to Interest Expense	-0.30	0.31	0.69	0.01	-0.34	-0.12	0.70	-0.31	0.15	-1.28	0.65
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.27	1.24	1.20	1.15	1.14	1.14	1.03	1.00	0.88	1.01	0.80
Accounts Receivable Turnover	7.58	8.07	7.92	7.65	7.69	8.28	8.21	7.58	7.47	9.07	7.68
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	109.19	106.77	99.08	99.94	93.92	87.54	79.61	77.44	70.81	64.53	55.45
Accounts Payable Turnover	38.55	41.73	34.96	34.88	30.85	34.77	30.22	27.66	25.04	24.37	23.08
Days Sales Outstanding (DSO)	48.16	45.23	46.11	47.71	47.48	44.08	44.46	48.15	48.85	40.24	47.55
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	9.47	8.75	10.44	10.46	11.83	10.50	12.08	13.20	14.58	14.98	15.81
Cash Conversion Cycle (CCC)	38.69	36.48	35.67	37.24	35.65	33.59	32.38	34.95	34.27	25.26	31.73
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,137	1,073	1,083	1,117	1,145	1,112	1,175	1,253	1,262	1,265	1,501
Invested Capital Turnover	1.83	1.85	1.76	1.65	1.60	1.59	1.40	1.37	1.13	1.39	1.05
Increase / (Decrease) in Invested Capital	-7.62	-39	-93	-137	-117	-153	-325	-177	-664	-36	25
Enterprise Value (EV)	2,285	2,097	2,238	1,766	1,760	1,753	1,508	1,574	1,491	1,416	1,552
Market Capitalization	1,048	900	999	531	479	511	227	314	193	145	279
Book Value per Share	($0.51)	($0.64)	($0.81)	($0.62)	($0.71)	($0.68)	($0.56)	($0.04)	($0.19)	($0.03)	$1.23
Tangible Book Value per Share	($6.38)	($6.56)	($6.73)	($6.58)	($6.68)	($6.70)	($6.59)	($6.80)	($6.96)	($6.79)	($6.66)
Total Capital	1,208	1,157	1,161	1,164	1,187	1,156	1,224	1,281	1,296	1,284	1,564
Total Debt	1,309	1,281	1,318	1,283	1,323	1,286	1,329	1,288	1,332	1,290	1,336
Total Long-Term Debt	1,299	1,272	1,309	1,274	1,314	1,276	1,320	1,279	1,323	1,281	1,327
Net Debt	1,237	1,197	1,239	1,235	1,281	1,242	1,281	1,260	1,298	1,271	1,273
Capital Expenditures (CapEx)	2.35	1.53	2.21	1.27	1.31	1.57	1.13	1.30	2.12	3.21	2.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-43	-85	-94	-64	-79	-75	-85	-73	-92	-67	-94
Debt-free Net Working Capital (DFNWC)	29	-0.30	-15	-16	-37	-31	-37	-45	-58	-48	-30
Net Working Capital (NWC)	19	-9.50	-25	-25	-46	-40	-46	-54	-67	-57	-40
Net Nonoperating Expense (NNE)	21	20	67	116	-160	46	49	13	44	95	-19
Net Nonoperating Obligations (NNO)	1,237	1,197	1,239	1,235	1,281	1,242	1,281	1,260	1,298	1,271	1,273
Total Depreciation and Amortization (D&A)	4.24	4.11	3.90	-2.14	10	-8.01	17	0.55	9.70	12	19
Debt-free, Cash-free Net Working Capital to Revenue	-2.05%	-4.18%	-4.74%	-3.26%	-4.13%	-3.94%	-4.56%	-3.99%	-5.13%	-3.73%	-6.00%
Debt-free Net Working Capital to Revenue	1.36%	-0.01%	-0.78%	-0.82%	-1.91%	-1.62%	-1.97%	-2.46%	-3.22%	-2.66%	-1.94%
Net Working Capital to Revenue	0.92%	-0.47%	-1.24%	-1.29%	-2.39%	-2.10%	-2.47%	-2.96%	-3.73%	-3.17%	-2.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.03	$0.15	($0.22)	$0.07	($0.06)	($0.14)	($0.54)	$0.14	($0.17)	($1.28)	$0.13
Adjusted Weighted Average Basic Shares Outstanding	194.67M	192.89M	193.36M	192.60M	192.24M	189.96M	189.14M	189.07M	189.05M	185.55M	186.11M
Adjusted Diluted Earnings per Share	$0.03	$0.15	($0.22)	$0.07	($0.06)	($0.13)	($0.54)	$0.13	($0.17)	($1.28)	$0.13
Adjusted Weighted Average Diluted Shares Outstanding	206.24M	192.89M	193.36M	196.87M	192.24M	189.96M	189.14M	189.74M	189.05M	185.55M	186.17M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	195.09M	195.09M	193.23M	193.23M	192.38M	192.38M	190.73M	190.43M	185.86M	185.86M	185.92M
Normalized Net Operating Profit after Tax (NOPAT)	27	33	24	26	16	21	20	26	12	-143	3.35
Normalized NOPAT Margin	4.75%	6.34%	4.70%	5.15%	3.26%	4.28%	4.28%	5.56%	2.66%	-31.72%	0.76%
Pre Tax Income Margin	1.81%	5.18%	-5.37%	0.79%	0.30%	-6.60%	-21.29%	5.25%	-6.52%	-53.01%	4.88%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.28	1.70	0.30	1.10	1.04	0.20	-1.57	1.65	0.15	-6.05	1.75
NOPAT to Interest Expense	0.73	1.30	0.61	3.28	-4.32	0.52	-1.35	1.02	0.34	-4.21	0.19
EBIT Less CapEx to Interest Expense	1.21	1.66	0.24	1.07	1.00	0.16	-1.60	1.62	0.09	-6.14	1.66
NOPAT Less CapEx to Interest Expense	0.66	1.26	0.55	3.24	-4.36	0.48	-1.38	0.99	0.28	-4.31	0.09
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Aveanna Healthcare's Financials

When does Aveanna Healthcare's financial year end?

According to the most recent income statement we have on file, Aveanna Healthcare's fiscal year ends in December. Their fiscal year 2024 ended on December 28, 2024.

How has Aveanna Healthcare's net income changed over the last 4 years?

Aveanna Healthcare's net income appears to be on a downward trend, with a most recent value of -$10.93 million in 2024, falling from -$76.52 million in 2020. The previous period was -$134.52 million in 2023. See where experts think Aveanna Healthcare is headed by visiting Aveanna Healthcare's forecast page.

What is Aveanna Healthcare's operating income?

Aveanna Healthcare's total operating income in 2024 was $139.79 million, based on the following breakdown:

Total Gross Profit: $635.54 million
Total Operating Expenses: $495.76 million

How has Aveanna Healthcare revenue changed over the last 4 years?

Over the last 4 years, Aveanna Healthcare's total revenue changed from $1.38 billion in 2020 to $2.02 billion in 2024, a change of 46.3%.

How much debt does Aveanna Healthcare have?

Aveanna Healthcare's total liabilities were at $1.79 billion at the end of 2024, a 2.6% increase from 2023, and a 13.2% increase since 2020.

How much cash does Aveanna Healthcare have?

In the past 4 years, Aveanna Healthcare's cash and equivalents has ranged from $19.22 million in 2022 to $137.35 million in 2020, and is currently $84.29 million as of their latest financial filing in 2024.

How has Aveanna Healthcare's book value per share changed over the last 4 years?

Over the last 4 years, Aveanna Healthcare's book value per share changed from 1.94 in 2020 to -0.64 in 2024, a change of -133.0%.

Related Companies

This page (NASDAQ:AVAH) was last updated on 5/22/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aveanna Healthcare (AVAH) Financials

Frequently Asked Questions About Aveanna Healthcare's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aveanna Healthcare (AVAH) Financials

Annual Income Statements for Aveanna Healthcare

Quarterly Income Statements for Aveanna Healthcare

Annual Cash Flow Statements for Aveanna Healthcare

Quarterly Cash Flow Statements for Aveanna Healthcare

Annual Balance Sheets for Aveanna Healthcare

Quarterly Balance Sheets for Aveanna Healthcare

Annual Metrics And Ratios for Aveanna Healthcare

Quarterly Metrics And Ratios for Aveanna Healthcare

Frequently Asked Questions About Aveanna Healthcare's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools